Biological Target

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to...

To treat genetic diseases, CAMP4 is targeting a type of RNA whose role in gene expression was first described by co-founder and MIT Professor Richard Young.

The availability of suzetrigine may represent a critical step in addressing the nation's pain management crisis. While questions remain about its cost, adoption, and long-term efficacy, its novel mechanism and positive clinical results offer a promising alternative to opioids.

Better targeting, optimization, earlier treatment create potential for increased use

Several medications now calm painful inflammation in the intestines. Diets free of ultraprocessed foods also help

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care

Personalized mRNA vaccines show promise as a pancreatic cancer treatment, according to a small, early stage trial published Wednesday.

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But experts say it can't replace opioids

Key innovations from the ASH annual meeting

A new study compares the competing weight-loss medications Wegovy and Zepbound, and a clear winner emerges.

An endocrinologist answers some of the tough questions that arise from discordant results on thyroid testing and how to talk to patients about thyroid disease.

Scientists pinpointed 80 gene variants, including eight tied to fatty acid metabolism, that may cause breast cancer in some people, new research suggests.

TKIs are the first-line of defense, but 'the more options we have the better,' expert says

New VMAT2 formulations, case reports, screening tools, and long-term data in 2024

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

First once-weekly subcutaneous prophylactic option for hemophilia B

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a trials. While other RSV treatments and a vaccine are approved for prevention, EDP-323 could become the first antiviral drug specifically designed to treat RSV infections. The drug has shown a significant reduction in viral load and symptoms in early trials, positioning it as a potential…

Topical/skin-directed therapies are best for early-stage disease or in combination with systemic therapies in advanced disease, according to Dr Arron Mangold.

Research on the ways that immune cells are activated reveals a possible preliminary step for developing a cure for the autoimmune disease, Lupus.

Simplified and more aggressive targets are among the significant changes to the updated hypertension guidelines by the European Society of Cardiology.